About this collection

Recent Submissions

  • A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function 

    Azaro, A; Rodón, J; Machiels, J-P; Rottey, S; Damian, S; Baird, R; Garcia-Corbacho, J et al. (Springer, 2016-12-01)
    $\textbf{PURPOSE}$ Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal ...
  • Trastuzumab-associated cardiac events in the Persephone trial 

    Earl, Helena M.; Vallier, Anne-Laure; Dunn, Janet; Loi, Shrushma; Ogburn, Emma; McAdam, Karen; Hughes-Davies, Luke et al. (Nature Publishing Group, 2016-11-22)
    PURPOSE: We report cardiac events in the Persephone trial which compares six to twelve months adjuvant trastuzumab in women with confirmed HER2 positive, early stage breast cancer. PATIENTS AND METHODS: Clinical cardiac ...
  • A Comprehensive Single Institutional Review of 2 Years in a Designated Fast-Track Sarcoma Diagnostic Clinic Linked with a Sarcoma Specialist Advisory Group: Meeting the Target but Failing the Task? 

    Szucs, Zoltan; Davidson, Dochka; Wong, Han Hsi; Horan, Gail; Bearcroft, Philip W. P.; Grant, Ian; Grimer, Robert et al. (Hindawi Publishing Corporation, 2016-06-02)
    Background. National guidelines prompted the implementation of a designated two-week wait referral pathway to facilitate the early diagnosis of sarcomas, to improve treatment outcomes. Methods. Patients referred to the ...
  • Clinical development of new drug–radiotherapy combinations 

    Sharma, Ricky A.; Plummer, Ruth; Stock, Julie K.; Greenhalgh, Tessa A.; Ataman, Ozlem; Kelly, Stephen; Clay, Robert et al. (Nature Publishing Group, 2016-06-01)
    In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ...

View more